학술논문

The ECHELON-2 Trial: Results of a Randomized, Double-Blind, Active-Controlled Phase 3 Study of Brentuximab Vedotin and CHP (A plus CHP) Versus CHOP in the Frontline Treatment of Patients with CD30+Peripheral T-Cell Lymphomas